Ucb
UCB, or UCB S.A., is a global biopharmaceutical company headquartered in Belgium. Founded in 1928, UCB has established itself as a leader in the biopharmaceutical industry, focusing on the development of innovative therapies for neurological and immunological disorders. With a strong presence in Europe and North America, UCB is dedicated to improving the lives of patients through its core products, including treatments for epilepsy, Parkinson's disease, and autoimmune conditions. The company is renowned for its commitment to research and development, which has led to significant milestones such as the launch of several groundbreaking therapies. UCB's unique approach combines advanced science with patient-centric solutions, positioning it as a key player in the global healthcare market. With a robust pipeline and a focus on unmet medical needs, UCB continues to make notable strides in the biopharmaceutical landscape.
DitchCarbon Score
How does Ucb's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ucb's score of 75 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Ucb's reported carbon emissions
In 2023, UCB reported total carbon emissions of approximately 85,332,000 kg CO2e. This figure includes 85,332,000 kg CO2e from Scope 1 emissions, which encompass direct emissions from owned or controlled sources, and 22,167,000 kg CO2e from Scope 2 emissions, related to indirect emissions from the generation of purchased electricity. Additionally, UCB's Scope 3 emissions totalled about 63,165,000 kg CO2e, which includes emissions from business travel, employee commuting, and purchased goods and services. UCB has set ambitious climate commitments, aiming to reduce its absolute Scope 1, 2, and 3 greenhouse gas emissions by 38% by 2030, using 2015 as the base year. Furthermore, the company has pledged that 60% of its suppliers, based on emissions, will have science-based targets by 2025. These targets align with the Science Based Targets initiative (SBTi) and are classified as consistent with the reductions necessary to limit global warming to well below 2°C. Overall, UCB's commitment to sustainability reflects a proactive approach to addressing climate change within the pharmaceutical and biotechnology sector, demonstrating a clear pathway towards significant emissions reductions in the coming years.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 56,578,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 28,138,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 00,000,000 |
| Scope 3 | 46,734,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ucb is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
